Spero Therapeutics (SPRO) Preferred Dividend Payments (2016 - 2017)
Spero Therapeutics posted quarterly Preferred Dividend Payments of $833000.0 for Q4 2017, down 9.26% year-on-year from $918000.0 in Q4 2016, and down 59.41% on a QoQ basis from $2.1 million in Q3 2017.
Spero Therapeutics (SPRO) has 2 years of Preferred Dividend Payments data on file, last reported at $833000.0 in Q4 2017.
- For the quarter ending Q4 2017, Preferred Dividend Payments fell 9.26% year-over-year to $833000.0; the trailing twelve-month figure through Dec 2017 stood at $6.1 million (changed N/A YoY), and the FY2017 full-year result was $6.1 million, up 78.61% from the prior year.
- Preferred Dividend Payments for Q4 2017 stood at $833000.0, down from $2.1 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $2.1 million in Q3 2017 and bottomed at $833000.0 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 833,000.00 |
| Sep 30, 2017 | 2.05 Mn |
| Jun 30, 2017 | 2.03 Mn |
| Mar 31, 2017 | 1.24 Mn |
| Dec 31, 2016 | 918,000.00 |
| Sep 30, 2016 | 916,000.00 |